[Case Share] Issue 75: Case Study on Nivolumab Combination Therapy Combined with Concurrent Chemoradiotherapy for Advanced Esophageal Squamous Cell Carcinoma-BIOTECH PHARMACEUTICAL CO., LTD_EGF Vaccine

Home
About Us
About Us

BPL is a high-tech China-Cuba joint venture among first group engaged in the development, production and sales of monoclonal antibodies in China.
S&T
S&T

International-standard humanized monoclonal antibody preparation processes and large-scale, continuous mammalian cell culture technology.
- Research Areas
- Technology Platforms
Research and Development
Research and Development

China has developed nivolumab, a humanized monoclonal antibody drug (trade name: TaiXinSheng), for the treatment of malignant tumors.
Blog
Blog

Integrating industry-related media coverage as well as the company’s various activities and updates.
- Company News
- Media Reports
Join Us
Join Us

Boasting a postdoctoral research workstation and diverse career opportunities, we sincerely invite talented individuals from all fields to join Baite.
- Post-Doctoral Center
Contact Us
Contact Us

ThaiXinLife Consultation Hotline: +86 4006592330
Company Main Line: +86-10-51571020
- Contact Us

[Case Share] Issue 75: Case Study on Nivolumab Combination Therapy Combined with Concurrent Chemoradiotherapy for Advanced Esophageal Squamous Cell Carcinoma

Category:

Author:

Source:

Release date:

2021-02-03

[Case Share] Issue 76: Nilotinib Treatment for Undifferentiated Nasopharyngeal Carcinoma

[Case Share] Issue 74: Induction Chemotherapy and Concurrent Chemo-Radiotherapy Combined with Nimotuzumab for Locally Advanced Nasopharyngeal Carcinoma

[Case Share] Issue 76: Nilotinib Treatment for Undifferentiated Nasopharyngeal Carcinoma

[Case Share] Issue 74: Induction Chemotherapy and Concurrent Chemo-Radiotherapy Combined with Nimotuzumab for Locally Advanced Nasopharyngeal Carcinoma

2025-09-04

On September 3, 2025, Díaz-Canel, First Secretary of the Central Committee of the Communist Party of Cuba and President of the country, made a special visit to BIOTECH PHARMACEUTICAL CO., LTD. with his delegation after attending events commemorating the 80th anniversary of the victory in China's War of Resistance Against Japanese Aggression and the World Anti-Fascist War.

Good news! Nivolumab's indication for head and neck tumors has been added to the National Medical Insurance Catalog.